Skip to main content
Equibles
PMN logo

PMN · ProMIS Neurosciences Inc. · Metrics

Track PMN — free

Use PMN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PMN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.56 +0.16 (+1.19%) At close · Sep 11
Rebalance outlook locked
Market Cap
$121.60M
Shares
8.97M

PMN metrics

46 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$13.56
Market cap
$121.60M

Price action

20 metrics
Price change (1W)
+3.9%
Price change (30D)
-9.4%
Price change (3M)
+25.2%
Price change (6M)
-32.8%
Price change (YTD)
+96.2%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
96.2%
Annualized volatility (3M)
99.3%
Beta
1.0
RSI (14D)
47.5
Price vs SMA 50
-4.0%
Price vs SMA 200
—
Avg volume (3M)
87,107
Relative volume
0.6
Average dollar volume
$1.22M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
8.97M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.4
reciprocal yield 41.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-35.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$43.43M
Net income (TTM)
−$42.23M
Trailing 12 months
Diluted EPS (TTM)
$-12.62
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.58

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
-1,529.3%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-959.7%
Shares change YoY
+555.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-85.5%
Return on assets
-74.5%
Debt / equity
—
Current ratio
7.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$53.43M
Total assets
$56.69M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$42.11M
Capital expenditures (TTM)
—
R&D (TTM)
$35.66M
SG&A (TTM)
—
Stock compensation (TTM)
$998,637
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
27
13F filer change QoQ
+2
Institutional ownership
71.4%

Short interest

3 metrics
Short interest
2.9%
Latest settlement · 9.4 days to cover
Days to cover
9.4d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
$30,324
Insider-sentiment score
78 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1374339 CUSIP 74346M505 13F (30d) 21 filings 21 filers Visit website Investor relations